March 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
May 2024 in “Reactions weekly”
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
December 2003 in “British Journal of Urology”
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
14 citations
,
May 2005 in “Steroids” A new method was developed to make finasteride for treating hair loss.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
20 citations
,
January 2004 in “PubMed Central” 5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
29 citations
,
July 2012 in “The Journal of Sexual Medicine” Rats had lasting erectile problems after stopping a certain medication.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
21 citations
,
January 2010 in “JOURNAL OF HEALTH SCIENCE” Abietic acid from pine resin can effectively inhibit testosterone 5α-reductase.
May 2024 in “Deleted Journal” Dutasteride effectively treats hair loss in men who don't respond to finasteride.
Dutasteride may become the top choice for treating hair loss.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
June 2019 in “Reactions Weekly”
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
13 citations
,
September 2011 in “International Urology and Nephrology”
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
These medications for BPH have known risks and may have new side effects.
June 2023 in “Sri Lanka Journal of Menopause” 5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.